EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of mirikizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease: Summary results from the Phase 3 VIVID-1 trial

B. Siegmund, M. Ferrante, V. Jairath, G. D’Haens, S. Maier, M. Protic, W. Crandall, H. Carlier, N. Morris, S. Zeissig

Zeitschrift für Gastroenterologie · 01.09.2024 · 62 (09) · e596-e597

DOI: 10.1055/s-0044-1789692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.09.2024. Verfasst von B. Siegmund und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Mirikizumab is a selective IL23p19 monoclonal antibody approved for the treatment of ulcerative colitis (UC). We present efficacy and safety data for mirikizumab vs placebo (PBO) in patients with moderately-to-severely active Crohn’s disease (CD) up to Week (W) 52 from the Phase 3 treat-through VIVID-1 trial (NCT03926130).

Methods

Adult patients (N=1065) were randomized 6:2:3 to receive intravenous (IV) mirikizumab (n=579) 900mg at W0, 4, and 8, then 300mg subcutaneously (SC) every 4Ws (Q4W) from W12 to W52, PBO (n=199), or ustekinumab (n=287; results vs mirikizumab previously presented) ~6 mg/kg IV at W0, then 90 mg SC Q8W from W8 to 48. PBO responders at W12 continued PBO to W52; PBO non-responders switched to mirikizumab induction then maintenance. The co-primary composite endpoints were: 1) Patient-Reported Outcome (PRO) clinical response at W12 and endoscopic response (by Simple Endoscopic Score SES-CD) at W52, and 2) PRO clinical response at W12 and clinical remission by Crohn’s Disease Activity Index (CDAI) at W52. Adjusted risk differences were calculated, with comparisons performed by CMH test. Fisher's exact test was used for comparisons performed within subgroups. Non-responder imputation was used. Fig. 1 Results: Baseline characteristics were similar across treatment groups ([ Table 1 ]). Both co-primary composite endpoints ([ Figs 1a, c ]; all p

Zitieren

APA

Siegmund, B., Ferrante, M., Jairath, V., D’Haens, G., Maier, S., Protic, M., Crandall, W., Carlier, H., Morris, N., & Zeissig, S. (2024). Efficacy and safety of mirikizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease: Summary results from the Phase 3 VIVID-1 trial. Zeitschrift für Gastroenterologie, 62(09), e596-e597. https://doi.org/10.1055/s-0044-1789692

Vancouver

Siegmund B, Ferrante M, Jairath V, D’Haens G, Maier S, Protic M, et al. Efficacy and safety of mirikizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease: Summary results from the Phase 3 VIVID-1 trial. Zeitschrift für Gastroenterologie. 2024;62(09):e596-e597. doi:10.1055/s-0044-1789692

BibTeX
@article{Siegmund2024,
  author = {Siegmund, B. and Ferrante, M. and Jairath, V. and D’Haens, G. and Maier, S. and Protic, M. and Crandall, W. and Carlier, H. and Morris, N. and Zeissig, S.},
  title = {Efficacy and safety of mirikizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease: Summary results from the Phase 3 VIVID-1 trial},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2024},
  volume = {62},
  number = {09},
  pages = {e596--e597},
  doi = {10.1055/s-0044-1789692}
}
Kostenlos starten →